Abstract
Tuberculosis (TB), an ongoing public health threat, is worsened by the emergence of drug resistance. With an estimated 630000 cases per year of multidrug resistant (MDR)-TB, and 9% of those being extensively drug resistant (XDR)-TB, there is an urgent need for new and more effective anti-TB drugs. New TB treatment regimens should be able to shorten the duration of therapy that currently takes at least six months. The non-compliance with this long treatment duration is one of the reasons for the development of drug resistance. In spite of the difficulties and alleged lack of interest from the pharmaceutical industry for the discovery and development of new antibiotics, several new or repurposed drugs are being evaluated in clinical trials. This review article summarizes the information available and presents an update on the drugs currently in clinical trials for TB and briefly introduces some new compounds in pre-clinical development.
Keywords: Antibiotics, clinical trials, drug development, drug resistance, tuberculosis.
Current Medicinal Chemistry
Title:Tuberculosis Clinical Trial Update and the Current Anti-Tuberculosis Drug Portfolio
Volume: 20 Issue: 30
Author(s): Juan Carlos Palomino and Anandi Martin
Affiliation:
- Laboratory of Microbiology, Department of Biochemistry & Microbiology, Ghent University, 9000 Gent Belgium.,Belgium
Keywords: Antibiotics, clinical trials, drug development, drug resistance, tuberculosis.
Abstract: Tuberculosis (TB), an ongoing public health threat, is worsened by the emergence of drug resistance. With an estimated 630000 cases per year of multidrug resistant (MDR)-TB, and 9% of those being extensively drug resistant (XDR)-TB, there is an urgent need for new and more effective anti-TB drugs. New TB treatment regimens should be able to shorten the duration of therapy that currently takes at least six months. The non-compliance with this long treatment duration is one of the reasons for the development of drug resistance. In spite of the difficulties and alleged lack of interest from the pharmaceutical industry for the discovery and development of new antibiotics, several new or repurposed drugs are being evaluated in clinical trials. This review article summarizes the information available and presents an update on the drugs currently in clinical trials for TB and briefly introduces some new compounds in pre-clinical development.
Export Options
About this article
Cite this article as:
Palomino Carlos Juan and Martin Anandi, Tuberculosis Clinical Trial Update and the Current Anti-Tuberculosis Drug Portfolio, Current Medicinal Chemistry 2013; 20(30) . https://dx.doi.org/10.2174/09298673113209990166
DOI https://dx.doi.org/10.2174/09298673113209990166 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Recent Advances in Methodologies for the Discovery of Antimycobacterial Drugs
Current Bioactive Compounds Programs to Facilitate Tuberculosis Drug Discovery: The Tuberculosis Antimicrobial Acquisition and Coordinating Facility
Infectious Disorders - Drug Targets New Approaches to Target the Mycolic Acid Biosynthesis Pathway for the Development of Tuberculosis Therapeutics
Current Pharmaceutical Design Tuberculosis Therapeutics: Past Achievements, Present Road-Blocks and Future Perspectives
Letters in Drug Design & Discovery Synthesis and Molecular Docking Studies of Glucose-linked Isonicotinoyl- 1,3,4-Thiadiazolidines as Antitubercular Agents
Letters in Organic Chemistry Kinase Targets for Mycolic Acid Biosynthesis in Mycobacterium tuberculosis
Current Molecular Pharmacology Microwave-assisted Synthesis of 2-Styrylquinoline-4-carboxylic Acids as Antitubercular Agents
Medicinal Chemistry Discovery of Potential Dual Inhibitors Against Lipases Rv0183 and Rv3802c for Tuberculosis Therapeutics
Letters in Drug Design & Discovery Identifying Key Regulator Genes for Tuberculosis by Differential Co- Expression Analysis of Gene Expression Profiling
Current Bioinformatics A HR-MS Based Method for the Determination of Chorismate Synthase Activity
Protein & Peptide Letters Recent Advances in Tuberculosis Vaccine Development
Current Respiratory Medicine Reviews The TB Structural Genomics Consortium: Providing a Structural Foundation for Drug Discovery
Current Drug Targets - Infectious Disorders Scanning the Genome of Mycobacterium tuberculosis to Identify Potential Lectins
Protein & Peptide Letters Evaluation of Substituted Benzaldehydes Against Mycobacterium tuberculosis
Letters in Drug Design & Discovery Silicosis in Current Scenario: A Review of Literature
Current Respiratory Medicine Reviews Vitamins Based Novel Target Pathways/Molecules as Possible Emerging Drug Targets for the Management of Tuberculosis
Medicinal Chemistry Current Prospects of Synthetic Curcumin Analogs and Chalcone Derivatives Against Mycobacterium Tuberculosis
Medicinal Chemistry Nanoemulsion for the Effective Treatment and Management of Anti-tubercular Drug Therapy
Recent Patents on Anti-Infective Drug Discovery Advances in TB Vaccinology
Current Respiratory Medicine Reviews In Vitro and In Vivo Activities of New Rifamycin Derivatives Against Mycobacterial Infections
Current Pharmaceutical Design